Omeros Corporation (NASDAQ:OMER) on 2 June announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. Omeros Corporation (NASDAQ:OMER) weekly performance is 35.85%. On last trading day company shares ended up $15.50. Analysts mean target price for the company is $32.80. Omeros Corporation (NASDAQ:OMER) distance from 50-day simple moving average (SMA50) is 32.25%.
On May 19, 2014, Ophthotech Corporation (NASDAQ:OPHT) entered into a Licensing and Commercialization Agreement (the “Agreement”) with Novartis Pharma AG (“Novartis”). Ophthotech Corp (NASDAQ:OPHT) shares fell -4.04% in last trading session and ended the day on $44.44. OPHT return on assets is -36.00%.Ophthotech Corp (NASDAQ:OPHT) quarterly performance is 21.72%.
Vital TherapiesInc. (NYSE:VTL) issued its quarterly earnings data on 3 June, Tuesday. The company reported ($24.49) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.54) by $23.95, StockRatingsNetwork.com reports. Vital Therapies Inc. (NASDAQ:VTL) shares moved up 21.17% in last trading session and was closed at $23.75, while trading in range of $19.31 – $24.40. Vital Therapies Inc. (NASDAQ:VTL) year to date (YTD) performance is 97.92%.
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases announced that company management will present at Jefferies Gene Therapy Summit on Monday, June 16, 2014 in Boston. Sue Washer, President and CEO will provide a corporate overview discussing the company’s lead programs in ophthalmology, including X-linked Retinoschisis (XLRS), Achromatopsia (ACHM) and X-linked Retinitis Pigmentosa (XLRP). In addition, Ms. Washer will participate in an ophthalmology panel Q&A hosted by Dr. Jeffery Heier, Vitreoretinal Specialist at Ophthalmic Consultants of Boston. Applied Genetic Technologies Corp (NASDAQ:AGTC) ended the last trading day at $25.29. Company weekly volatility is calculated as 14.44% and price to cash ratio as 14.53.Applied Genetic Technologies Corp (NASDAQ:AGTC) showed a positive weekly performance of 26.26%.
Leave a Reply